Physician profile
Michael S Kobernick
NPI 1659305076
$137,173.52
in general payments reported to CMS, 2019-2025
26 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $7,550 · 2021: $15K · 2022: $20K · 2023: $26K · 2024: $22K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Travel and Lodging: $11K · Food and Beverage: $1,824 · Honoraria: $1,600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $78,774.25 |
| Travel and Lodging | $11,158.08 |
| Food and Beverage | $1,823.73 |
| Honoraria | $1,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $586.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19,402.24 | 2021-2025 | |
| Johnson & Johnson Health Care Systems INC. | $16,204.60 | 2023-2025 | Spravato |
| Incyte Corporation | $15,358.89 | 2020-2024 | Opzelura |
| Novo Nordisk INC | $14,085.98 | 2021-2025 | Saxenda |
| Biomerieux INC | $11,446.49 | 2024 | |
| Abbott Laboratories | $7,159.99 | 2025 | Afinion 2, Alere Cholestech Ldx, Afinion Hba1c Dx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $5,462.39 | 2023 | |
| Novartis Pharmaceuticals Corporation | $5,459.56 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $5,347.50 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $5,170.39 | 2023 | |
| Biogen, INC. | $4,550.00 | 2020-2021 | |
| Viiv Healthcare Company | $3,612.81 | 2023 | |
| Horizon Therapeutics Plc | $3,430.00 | 2020-2023 | Tepezza |
| Glaxosmithkline, LLC. | $2,600.00 | 2022 | |
| Sobi, INC | $2,212.00 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,145.15 | 2025 | |
| Astrazeneca Uk Limited | $2,000.00 | 2024 | |
| Emd Serono, INC. | $1,890.00 | 2025 | |
| Apellis Pharmaceuticals, INC. | $1,800.00 | 2022 | |
| Genentech USA, INC. | $1,760.00 | 2021 | |
| Invivyd INC | $1,700.00 | 2025 | Pemgarda |
| Eisai INC. | $1,290.00 | 2021 | |
| Amgen INC. | $1,277.50 | 2024 | Tepezza |
| Evoke Pharma, INC. | $1,200.00 | 2025 | |
| Ionis Pharmaceuticals, INC. | $425.00 | 2025 | Tryngolza |
| Boehringer Ingelheim International Gmbh | $183.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kobernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.